

ANNUAL REPORT

2025

swedenBIO

The Swedish Life Science Industry Organization

TABLE OF CONTENTS

Foreword	3	Network	10
Vision and Mission	4	International activities	13
The value of membership	5	Knowledge	18
Board	7	Policy & public affairs	24
Team	9		

For full financial reporting, we refer to the audited annual reports for the company SwedenBIO Service AB and the association SwedenBIO.

SwedenBIO delivers!

I cannot escape the feeling that a year flies by so fast when you're the CEO of SwedenBIO. It is only in hindsight, when sitting down to summarize the past year that I always become amazed by how much we actually have accomplished. In this regard, 2025 was no exception but yet another year where we delivered beyond our own expectations.

It's difficult to point to one single event or accomplishment as a sign of a successful year. I is rather the consistent delivery of top networking, knowledge, and policy work - as well as a ton of achievements that don't quite fit into these three categories - that signifies what SwedenBIO has been able to deliver in 2025.

Instead of detailing what we've been up to in 2025 in this column, I will let the annual report speak for itself. I am confident that you will agree that SwedenBIO has delivered great value for its members in many different ways. And with the continued expansion of our team, we are set to deliver once again in 2026. Stay tuned!

Jessica Martinsson



Vision and mission

SwedenBIO's vision is a nationally vibrant and internationally competitive life science industry in Sweden.

Our mission is to strengthen the competitiveness of the Swedish life science industry.

- 1** Building strong networks within life science in Sweden, Nordics and globally
- 2** Gathering, creating and sharing knowledge
- 3** Advocating and being a strong voice for the industry to influence policy

The value of membership

Being a member of SwedenBIO means more than just joining an organization – it signifies becoming part of a diverse and vibrant community that is actively shaping the future of Sweden’s life science industry. Through the membership companies gain direct access to a broad

network, valuable industry insights, a strong voice in the public debate, and exclusive offers and discounts. Together, we strengthen the industry’s competitiveness and drive long-term growth.



Our members are at the core of everything we do..

SwedenBIO works on behalf of its members to drive public policy, build strong networks, and accelerate business success. Your membership and engagement give SwedenBIO the strength, expertise, and legitimacy needed to effectively represent and advance the industry. At the same time, you gain insights and opportunities that support your own business development.

Our members are at the core of everything we do. We tailor our work to your needs and we work through member representatives to extend our reach. Our agile team creates meaningful opportunities for member-to-member connections and links to key stakeholders nationally and internationally—opening doors to new collaborations and business opportunities. Strategic partnerships further strengthen the ecosystem and deliver tangible value to our members.



The board




Anders Persson
AstraZeneca



Sara Corin
Cytiva



Renée Aguiar-Lucander
Hansa Biopharma



Mårten Winge
Pelago Bioscience



Hanna Sjöström
Neola Medical



Christine Wesström
Sobi



Carl Kilander
Partner, HealthCap



Jesper Ericsson
SymCel

A representative board with a long-term focus

The board comprised eight* members during 2025, with Anders Persson serving as chairman and Sara Corin as vice chairwoman.

The members were Renee Lucander, Mårten Winge, Hanna Sjöström, Christine Wesström, Carl Kilander, and Jesper Ericsson.

The board reflects the diversity of the member community, representing both large and small companies, as well as expertise in medtech, investment, and other sectors.

It focuses on the long-term development of SwedenBIO while regularly monitoring progress toward current goals and objectives.

*Tobias Lundin Gerdås, Roche, esigned from the board due to change of employer.





Team

The association's operations are led by a CEO who oversees the office. Jessica Martinsson is the CEO since March 1, 2023. The team expanded in 2025 with a newly created position as Key Account Manager. At the end of the year, the office consisted of 10 full-time employees.

The office serves also as an “air traffic control tower” for the representatives from the member companies that constitute SwedenBIO's expert network. The network is structured in working groups and task forces led by the member companies themselves in close cooperation with members of the team.



NETWORK





Through our events and gatherings, we strengthen the connections within the community as well as serve as a facilitator for actors that want to interact with the industry.

Executive dinner

The annual Executive dinner was held in conjunction with the association's annual meeting in May at Münchenbryggeriet in Stockholm. Around 200 executives from the industry were there to mingle and network. The Canadian ambassador to Sweden, Mr Jason LaTorre delivered a highly appreciated key note speech on the need for Sweden and Canada to intensify cooperation.



Almedalen

The SwedenBIO house in Almedalen was busy as usual in June and has become a de facto hub for the life science-community. We arranged several well-attended seminars, as well as our traditional and much appreciated garden mingle which once again was filled to the brim.

Summit

Our final event of the year, the SwedenBIO Summit, took place in January 2026 in Stockholm, and offered an program with inspirational behind-the-scenes stories from our member companies as well as the release of the Life Science Barometer report. The mingle at Summit is highly appreciated by the members, offering a nice wrap-up of the year.



Hesa Fredrik-AW

We continued our quarterly open doors after-work mingle for the life science community in Stockholm, first launched in 2023. It has become a cherished tradition attracting a diverse crowd for some laid-back networking. Many members have expressed their appreciation for this casual event with no sign-up or other formalities where they can meet new people.





INTERNATIONAL ACTIVITIES



Delegation to Singapore

A Swedish delegation visited Singapore in September 2025 to explore the country's health and life science ecosystem. Led by Jeanette Edblad, Director of the Office for Life Sciences at the Government Offices of Sweden, the delegation was organized by Swecare, Business Sweden, SwedenBIO, and financed by Vinnova.



Other events

During the year, SwedenBIO with its members has been present at several important partnering meetings such as JP Morgan week and BIO, both in the USA and London Life Science Week.

Building Bridges Between Swedish and Swiss Life Science

SwedenBIO has a long history of engaging with actors in Switzerland to help companies from both countries meet and do business. The exchanges and contacts have evolved over the years and matured to the extent that SwedenBIO arranged a Nordic delegation to Swiss Biotech Day in 2025. Seven companies joined the delegation that promoted Sweden and the Nordics through a dedicated pavilion as well as tailored visits and activities.



Gearing up for Stronger Nordic Life Science Cooperation

Beginning in January 2025, SwedenBIO's Nordic Community Manager, Sigrun Elfa Snæbjörnsdóttir, packed her bags and set out on a mission to connect with key stakeholders in the life science sector across all Nordic countries.





NLSDays 2025

Nordic Life Science Days continues to be the largest Nordic partnering conference for the life science industry. Since its inception in 2013, the event has nurtured a community of professionals from the life science world and is a unique place to do business. It has continued to evolve and attract a diverse crowd of actors from Sweden, the Nordics and beyond looking to connect, learn and be inspired.

NLSDays 2025 was held in Gothenburg for the first time ever and offered an exciting program with supersessions, a pitch competition for innovative Nordic startups, an innovation poster exhibition, company presentations and an exhibition floor with diverse companies from the Nordics and beyond. This edition of NLSDays attracted more than 1600 delegates, setting a new record in many categories of attendees.

a swedenbio event



1600+

DELEGATES



FROM 32 COUNTRIES

60%  NORDIC

40%  INTERNATIONAL

12 INTERNATIONAL DELEGATIONS



MORE THAN

230

EXHIBITING COMPANIES

160

INVESTORS REPRESENTING 89 COMPANIES

1041

SQM OF EXHIBITION AREA

3K+

SCHEDULED PARTNERING MEETINGS

OVER

200

SPEAKERS & PRESENTERS

70+

SPONSORS & SUPPORTERS

50%

INCREASE IN MEDIA AND PRESS

ATTENDANCE COMPARED TO LAST YEAR

190K+



SOCIAL MEDIA IMPRESSIONS

40%

AVERAGE NEWSLETTER OPEN RATE

How to kill the opportunity of setting up a
constructive academic collaboration in Sweden

How to successfully setup a collaboration
- listen and learn from there



KNOWLEDGE


TERMS SHEET FOR
RESEARCH
COLLABORATION

Life Science Barometer 2026

SwedenBIO presented the Life Science Barometer 2026 in January 2026.

The report shows that the industry continues its multi-year growth and remains a significant contributor to the Swedish economy. With net sales of SEK 508 billion, the sector accounts for nearly 10 percent of goods exports, making it the second-largest export sector.


The report also shows that the share of female CEOs has increased by five percentage points since the previous measurement and now stands at 31 percent.



The Swedish Drug Discovery and Development Pipeline 2026

The Swedish pipeline report for drug development, was published October 2025. It is based on a survey of Swedish companies and maps progress and trends within the country's pharmaceutical development sector.

The 2026 edition shows that the Swedish drug pipeline comprises 518 projects run by 152 companies headquartered in Sweden. About half of the projects are in the discovery or preclinical phase, and the other half are in the clinical phase. This impressive pipeline matches global pharmaceutical companies in the number of clinical assets and surpasses big pharma in the number of preclinical assets.



Seminars we arranged and co-arranged in 2025

Raising Capital in Life Science: What Investors Really Want to Know

Seminar by SwedenBIOs Finance Working Group in cooperation with Redeye, held in September 2025.

Growing your business in the US

Seminar by SwedenBIOs Business Strategy Working Group with DNB/Back Bay, held in June 2025

Unlocking Innovation: Best Practices for Corporate–Academic Partnerships

Seminar by SwedenBIOs IP Working Group, held in April 2025.



Clinical trials project



Study report shows how Sweden can strengthen its competitiveness in clinical trials

Between April 2024 - April 2025, SwedenBIO has been participating in a project titled **Strengthened Swedish Competitiveness for Clinical Trials (Stärkt svensk konkurrenskraft för kliniska prövningar)**, a study exploring key aspects of a Swedish partnership for clinical trials.

The project partners include Region Skåne, Region Stockholm, and Västra Götaland Region, as well as the industry associations Lif and SwedenBIO. The goal has been to investigate how a national partnership for clinical trials can be formed in Sweden.

SwedenBIO's main contribution to the project is to create and test a decision-making tool based on data-driven insights for strategic directions and prioritized areas. The focus is on industry-initiated pharmaceutical clinical trials.

The report, published June 2025, highlights that Sweden has strong advantages, such as high-quality healthcare, well-developed registries, and a strong tradition of collaboration. At the same time, it points to a number of obstacles that need to be addressed, including complex processes, limited resources within healthcare, and insufficient coordination between stakeholders.

SwedenBIO joins the advisory group for SweTrial

SweTrial is a national partnership tasked with strengthening Sweden's role in clinical trials and life science. The partnership operates under the Swedish Medical Products Agency, which has been commissioned by the government to implement a permanent initiative to improve the infrastructure for clinical trials in the country.

To ensure long-term and effective progress, SweTrial has established an advisory council with representatives from government agencies, healthcare, academia, and industry. Members are nominated by the organizations they represent and appointed by the Swedish Medical Products Agency. The term of office is two years, with the possibility of extension.


SwedenBIO is represented on the council by CEO Jessica Martinsson as a full member and by National Director Joanna Daffy Tiitus as a deputy. Industry associations such as Lif, Swedish Medtech, and ASCRO are also represented, along with representatives from academia and healthcare.



SwedenBIO updates industry standards for capital raising

SwedenBIO launched an updated version of the Industry Standard for Information Disclosure in Capital Raising within Life Science. The aim is to clarify what information a life science company should provide to prospective investors.


The work to develop the updated standard was led by SwedenBIO's finance working group, with contributions from other working groups to ensure that the recommendations are both relevant and comprehensive.



IP Term Sheet launched to strengthen corporate–academic collaborations

Presented during a SwedenBIO seminar on 29th April 2025, the term sheet is meant to help companies and academic actors to avoid common pitfalls and blind spots around IP when discussing collaborations.

The term sheet itself is a non-binding checklist covering both background IP rights and the “foreground” inventions that could potentially arise from a joint project. The term sheet was produced by the IP working group.





POLICY & PUBLIC AFFAIRS



NOVUM



As the importance of Swedish pharmaceutical exports and the industry at large is becoming an important economic factor – we need to have a stronger voice in the arena.

Our voice in the public debate has only grown stronger in 2025, as the record number of media mentions and debate articles attest to. The Trump administrations announced tariffs offered us many opportunities to highlight the threat to Swedish life science.

In general, SwedenBIO has become a much more visible voice in the public debate and within the industry, reflected in an increase in speaker invites from different actors as well as becoming a sought after voice by the media. We have also more decision-makers attend and speak at our events, compared to previous years.

SwedenBIO is also represented in several national advisory and decision-making bodies. During 2025, the association has been active in:

The Government's Advisory Group for Life Sciences

Industry representative in the Data-Driven Life Science

Research School (DDLs)

The National Board of Health and Welfare's

Stakeholder Collaboration Against AMR

The steering group for InfraLife (SciLifeLab)

Reference group for national life science statistics

(Vinnova)





SwedenBIO's CEO takes a seat on Europe's largest biotech industry body

SwedenBIO's CEO, Jessica Martinsson, was elected to the board of EuropaBio – Europe's largest and most influential biotechnology industry organization in mid 2025. The election took place during the organization's annual general meeting in Brussels.

In addition to her role on the board, she will also lead EuropaBio's SME platform, which brings together small and medium-sized biotech companies from across Europe, spanning the full breadth of the sector. The platform consists of EuropaBio and its national member organizations and, as of 2025, represents more than 4,500 biotech companies.

EuropaBio – The European Association for Bioindustries – is based in Brussels and was founded in 1996 to represent the interests of the biotechnology industry at the European level. The organization is a key player in dialogue with the European Parliament, the European Commission, and the Council of the European Union, with the aim of influencing legislation related to the development of biotechnology. EuropaBio represents stakeholders in both medical and industrial biotechnology.



Expert network

SwedenBIO engages its members through an expert network that gathers the participants in working groups and task forces. The network consists of nine working groups, as the IP group was upgraded into a full-fledged working group.

During 2025, the following groups were active:

- Research and Development
- Clinical Trials
- Public Affairs
- Production and Process Development
- Business Strategy
- Pandemic Preparedness
- Finance
- Medtech
- Intellectual Property

Our expert network has continued to be active and productive in 2025, acting as an important tool to identify, analyze, and address the challenges facing the industry with the support of its members.


We continued to leverage the full capacity of the expert network, which is composed of all representatives in our working groups, task forces and board, combined. The purpose of meeting all groups at once is to identify synergies between the groups, and how several groups may work on a similar question from different perspectives.

The expert network has held two workshops in 2025 to discuss and stake out the future of SwedenBIO as well to map key policy issues for our policy platform.



In 2025, SwedenBIO responded to the following public referrals:

- Proposals for the Simplification of the EU Medical Device Regulations (MDR/IVDR)
- Remissvar. SOU 2025:62 Ansvar för hälso- och sjukvården
- Remissvar avseende Europeiska kommissionens förslag på förordning Critical Medicines Act Diarienummer: S2025/00728
- Inspel till EU-kommissionens förslag om Biotech Act (tillsammans med Lif)
- Remissvar på Skatteincitament för forskning och utveckling – En översyn av FoU avdraget och expertskattereglerna
- EU Life Science Strategy Open Consultation
- Remissvar på Bättre tillsammans – Förslag till en uppdaterad nationell cancerstrategi





Media impact

2025 was a successful year in terms of shaping the narrative, highlighting and making Swedish Life Science known through media appearances. Notably, SwedenBIO achieved new record numbers on several key metrics.

13%

Increase in number of issued press releases

21%

Increase in number of published news articles

160%

Increase in media mentions

Numbers compared to 2024



sweden **BIO**

The Swedish Life Science Industry Organization

Wallingatan 24, 111 24 Stockholm
info@swedenbio.com

swedenbio.com